Differential expression of RON in small and non-small cell lung cancers

Genes Chromosomes and Cancer

Volumn 51, Issue 9, 2012, Pages 841-851

  Kanteti, Rajani ^a   Krishnaswamy, Soundararajan ^a,b   Catenacci, Daniel ^a   Tan, Yi Hung Carol ^a   El Hashani, Essam ^a   Cervantes, Gustavo ^a   Husain, Aliya N ^a   Tretiakova, Maria ^a   Vokes, Everett E ^a   Huet, Heather ^c   Salgia, Ravi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; PHOSPHOPROTEIN; PHOSPHOPROTEIN RON; PROTEIN RON; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; GENE FREQUENCY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOLECULAR WEIGHT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; APOPTOSIS; BRAIN NEOPLASMS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; LUNG; LUNG NEOPLASMS; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES; RNA, SMALL INTERFERING; SMALL CELL LUNG CARCINOMA; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; WOUND HEALING;

EID: 84863567840     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.21968     Document Type: Article

References (30)

1. Accornero P, Pavone LM, Baratta M. 2010. The scatter factor signaling pathways as therapeutic associated target in cancer therapy. Curr Med Chem 17: 2699-2712.
2. Angeloni D, Danilkovitch-Miagkova A, Ivanov SV, Breathnach R, Johnson BE, Leonard EJ, Lerman MI. 2000. Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chromosomes Cancer 29: 147-56.
3. Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ, Ellis LM. 2007. Tyrosine kinase receptor RON in human pancreatic cancer: Expression, function, and validation as a target. Cancer 109: 1030-1039.
4. Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY, Chang TY, Ho CL, Tzai TS, Chow NH. 2005. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer 92: 1906-1914.
5. Choong NW, Ma PC, Salgia R. 2005. Therapeutic targeting of receptor tyrosine kinases in lung cancer. Expert Opin Ther Targets 9: 533-559.
6. Choong NW, Salgia R, Vokes EE. 2007. Key signaling pathways and targets in lung cancer therapy. Clin Lung Cancer Suppl 2: S52-S60.
7. Correll, P. H., A. Iwama, S. Tondat, G. Mayrhofer, T. Suda, and A. Bernstein. 1997. Deregulated inflammatory response in mice lacking the STK/RON receptor tyrosine kinase. Genes Funct 1: 69-83.
8. Danilkovitch-Miagkova A, Angeloni D, Skeel A, Donley S, Lerman M, Leonard EJ. 2000. Integrin-mediated RON growth factor receptor phosphorylation requires tyrosine kinase activity of both the receptor and c-Src. J Biol Chem 275: 14783-14786.
9. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
10. Felsher DW. 2008. Oncogene addiction versus oncogene amnesia: Perhaps more than just a bad habit? Cancer Res 68: 3081-3086.
11. Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, Comoglio PM, Green MR, Riva S, Biamonti G. 2005. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell 22: 20881-890.
12. Ghigna C, De Toledo M, Bonomi S, Valacca C, Gallo S, Apicella M, Eperon I, Tazi J, Biamonti G. 2010. Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: Therapeutic potential of bifunctional oligonucleotides and indole derivatives. RNA Biol 7: 495-503.
13. Giaccone G, Rodriguez JA. 2005. EGFR inhibitors: What have we learned from the treatment of lung cancer? Nat Clin Pract Oncol 2: 554-561.
14. Gomes DA, Rodrigues MA, Leite MF, Gomez MV, Varnai P, Balla T, Bennett AM, Nathanson MH. 2007. MET must translocate to the nucleus to initiate calcium signals. J Biol Chem 283: 4344-4351.
15. Hirayama I, Ide M, Asao T, Kuwano H. 2007. Receptor protein tyrosine kinase Ron is highly expressed in colorectal mucosa of ulcerative colitis patients. Hepatogastroenterology 54: 1672-1675.
16. Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S, Faoro L, Cagle P, Husain AN, Vokes EE, Lang D, Salgia R. 2009a. PAX5 is expressed in small-cell lung cancer and positively regulates MET transcription. Lab Invest 89: 301-314.
17. Kanteti R, Yala S, Ferguson MK, Salgia R. 2009b. MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J Environ Pathol Toxicol Oncol 28: 89-98.
18. Li Z, Yao H, Guin S, Padhye SS, Zhou YQ, Wang MH. 2010. Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells. Int J Oncol 37: 473-482.
19. Lu Y, Yao HP, Wang MH. 2007. Multiple variants of the RON receptor tyrosine kinase: Biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett 257: 157-164.
20. Maggiora P, Lorenzato A, Fracchioli S, Costa B, Castagnaro M, Arisio R, Katsaros D, Massobrio M, Comoglio PM, Flavia Di Renzo M. 2003. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res 288: 382-389.
21. Oh JJ, West AR, Fishbein MC, Slamon DJ. 2002. A candidate tumor suppressor gene, H37, from the human lung cancer tumor suppressor locus 3p21.3. Cancer Res 62: 3207-3213.
22. Sakamoto O, Iwama A, Amitani R, Takehara T, Yamaguchi N, Yamamoto T, Masuyama K, Yamanaka T, Ando M, Suda T. 1997. Role of macrophage-stimulating protein and its receptor, RON tyrosine kinase, in ciliary motility. J Clin Invest 99: 701-709.
23. Sutherland LC, Wang K, Robinson AG. 2010. RBM5 as a putative tumor suppressor gene for lung cancer. J Thorac Oncol 5: 294-298.
24. Takano Y, Sakamoto O, Suga M, Suda T, Ando M. 2000. Elevated levels of macrophage-stimulating protein in induced sputum of patients with bronchiectasis. Respir Med 94: 784-790.
25. Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA, Waltz SE, Lowy AM. 2007. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 67: 6075-6082.
26. Wagh PK, Peace BE, Waltz SE. 2008. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 100: 1-33.
27. Wang MH, Zhou YQ, Chen YQ. 2002. Macrophage-stimulating protein and RON receptor tyrosine kinase: Potential regulators of macrophage inflammatory activities. Scand J Immunol 56: 545-553.
28. Wang MH, Lee W, Luo YL, Weis MT, Yao HP. 2007. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol 213: 402-411.
29. Welm AL, Sneddon JB, Taylor C, Nuyten DS, van de Vijver MJ, Hasegawa BH, Bishop JM. 2007. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci USA 104: 7570-7575.
30. Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA, Peace BE, Beauman SR, Collins MH, Waltz SE. 2006. Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta- catenin activation. Cancer Res 66: 11967-11974.